Donald Perry, MD
Sports Medicine · Birmingham, ALNPI 1669768537
Payments from drug & device makers
Across 137 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$298
- Novo Nordisk$273
- Lilly USA, LLC$259
- AbbVie$236
- Amarin Pharma, Inc.$197
- Biohaven Pharmaceutical Holding Company Ltd.$173
- plus $957 from 23 others
What the payments were for
- Food & beverage$2,392100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 11 | $298 |
| Novo Nordisk | 12 | $273 |
| Lilly USA, LLC | 16 | $259 |
| AbbVie(2 entities) | 23 | $236 |
| Amarin Pharma, Inc. | 5 | $197 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $173 |
| GSK | 9 | $136 |
| Biohaven Pharmaceuticals, Inc. | 5 | $107 |
| AstraZeneca | 7 | $93 |
| Pfizer | 5 | $76 |
| Boehringer Ingelheim | 4 | $67 |
| Teva Pharmaceuticals USA, Inc. | 4 | $49 |
| Gilead | 3 | $45 |
| Irhythm Technologies, Inc. | 2 | $41 |
| Merck | 3 | $36 |
| Dexcom, Inc. | 2 | $35 |
| Genentech USA, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Zimmer Biomet | 1 | $28 |
| Shire North American Group Inc | 2 | $25 |
| Johnson & Johnson | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Pacira Pharmaceuticals Incorporated | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| Nabriva Therapeutics, PLC | 1 | $12 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$141
- AIMOVIG$125
- Xultophy 100/3.6$103
How this compares
$2,392 in reported general payments places this provider in the 40th percentile of 108 sports medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 26 | $168 |
| Methylprednisolone | 14 | $89 |
| Prednisone | 12 | $74 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $36 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Birmingham
- Edward CainBirmingham$12.8M
- Ricardo ColbergBirmingham$271K
- Mark RogersBirmingham$94K
- Amit MomayaBirmingham$77K
- David AdkisonBirmingham$68K
- Christoper GarrettBirmingham$58K
- Reaves CrabtreeBirmingham$47K
- Amir ShahienBirmingham$45K
- Christopher CarterBirmingham$42K
- Christian MerrillBirmingham$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.